Interestingly, these antibodies do not inhibit binding of the α1 and α2 domains with receptors and allowed continued NKG2D–MICA interactions to inhibit murine tumor progression in mouse models and reduced human melanoma metastases in a humanized mouse model. The gene discussed is KLRK1; the disease is neoplasm.